Driving the mission

Ben co-founded Coherence after recognising the potential of next-generation neurotechnologies to treat cancer. He completed his PhD in the lab of bioelectronics and materials science pioneer Professor George Malliaras at the University of Cambridge, where his research focused on flexible spinal cord and brain interfaces. He previously developed and industrialised some of the world’s first intelligent drug delivery systems at Philips and Vectura.

Elise is an electrical engineer who also completed her PhD under Professor George Malliaras at the University of Cambridge. During that time, she focused on the electrical characteristics of cancer, bridging distant scientific fields and inspiring her to invent a new way to approach cancer, leading to the founding of Coherence. Previously, she designed sensors for F1 race cars and led technical teams at Siemens.

José is a mechanical engineer by training. He was previously Head of Product Development at Iota Biosciences (acquired by Astellas). José has brought multiple technologies to the clinic and into commercial reality via Abbott and Setpoint Medical.

Jason is a neuroscientist by training who previously led translation for the Google x GlaxoSmithKline joint venture, Galvani Bioelectronics. Prior to that, he focused on neuroscience research at Pfizer.

Nicole was Coherence’s first institutional believer as an investor at Blackbird Ventures, before joining the company. Working directly with CEO Ben Woodington, she helps shape Coherence's long-term vision of building a cancer therapy platform that learns. Leveraging her background as an Investor across both public and private markets, Nicole works across capital formation and commercial strategy. She holds a BCom (Honours) with majors in economics and finance from the University of Melbourne.

As Head of Quality at Coherence Neuro, Hanna draws on more than 17 years of experience at various start-ups, designing and commercializing healthcare technologies across the full risk spectrum, from simple disposables to active implantables. She has built ISO 13485-certified quality systems from the ground up and integrating agile development with rigorous design controls, so innovation can move quickly without compromising safety. She holds a B.S. in biomedical computation from Stanford.

An Oxford physics graduate who completed her PhD thesis on quantitative metabolic imaging of the brain using MRI. Hannah joined TTP, where she spent 10 years developing technology ranging from large multinationals to fast-moving start-ups. Hannah built and led the TTP Neurotechnology team, helping neurotech companies move from early concepts to clinic-ready devices. After a stint at Cellular Origins, a robotics and cell therapy start-up, Hannah joined Coherence as Product Development Lead

Jake is a mathematician and neuroscientist. He earned his PhD at the University of Oxford and previously served as a Research Fellow at the University of Cambridge, where he worked on large-scale systems neuroscience. Previously, he worked as a statistical analyst for the UK Ministry of Defence. Jake leads a team of researchers dedicated to discovering new neural biomarkers, biophysical modelling, and optimising treatment algorithms.